Genetic polymorphisms and the risk of accelerated renal function decline in women

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Cooper Worobey, Cynthia ^a   Fisher, Naomi D L ^b   Cox, David ^b   Forman, John P ^b   Curhan, Gary C ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADDUCIN; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; APOLIPOPROTEIN E; CREATININE; RAS PROTEIN;

ADULT; ARTICLE; BODY MASS; CAUCASIAN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANGIOTENSINOGEN; CALMODULIN-BINDING PROTEINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; RISK;

EID: 62849128205     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004787     Document Type: Article

References (53)

1. Wattanakit K, Coresh J, Muntner P, Marsh J, Folsom AR (2006) Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol 48: 1183-1189.
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, et al. (2004) Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860.
5. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, et al. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878.
6. Agarwal A, Williams GH, Fisher ND (2005) Genetics of human hypertension. Trends Endocrinol Metab 16: 127-133.
7. Miller JA, Scholey JW (2004) The impact of renin-angiotensin system polymorphisms on physiological and pathophysiological processes in humans. Curr Opin Nephrol Hypertens 13: 101-106.
8. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, et al. (1994) Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci U S A 91: 3999-4003.
9. Castellano M, Barlassina C, Muiesan ML, Beschi M, Cinelli A, et al. (1997) Alpha-adducin gene polymorphism and cardiovascular phenotypes in a general population. J Hypertens 15: 1707-1710.
10. Hsu CC, Kao WH, Coresh J, Pankow JS, Marsh-Manzi J, et al. (2005) Apolipoprotein E and progression of chronic kidney disease. Jama 293: 2892-2899.
11. Butkus DE (2002) Familial clustering of end-stage renal disease in Mississippi. J Miss State Med Assoc 43: 71-77.
12. Freedman BI, Soucie JM, McClellan WM (1997) Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 8: 1942-1945.
13. Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39: 940-945.
14. Seaquist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320: 1161-1165.
15. Spray BJ, Atassi NG, Tuttle AB, Freedman BI (1995) Familial risk, age at onset, and cause of end-stage renal disease in white Americans. J Am Soc Nephrol 5: 1806-1810.
16. Mayeux R (2005) Mapping the new frontier: complex genetic disorders. J Clin Invest 115: 1404-1407.
17. Miller JA, Thai K, Scholey JW (1999) Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 56: 2173-2180.
18. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, et al. (1997) Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 60: 1448-1460.
19. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, et al. (1992) Molecular basis of human hypertension: role of angiotensinogen. Cell 71: 169-180.
20. Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P (2001) Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int 60: 46-54.
21. Rogus JJ, Moczulski D, Freire MB, Yang Y, Warram JH, et al. (1998) Diabetic nephropathy is associated with AGT polymorphism T235: results of a family-based study. Hypertension 31: 627-631.
22. Goto S, Narita I, Saito N, Watanabe Y, Yamazaki H, et al. (2002) A(-20)C polymorphism of the angiotensinogen gene and progression of IgA nephropathy. Kidney Int 62: 980-985.
23. Nakanishi K, Sako M, Yata N, Aoyagi N, Nozu K, et al. (2004) A-20C angiotensinogen gene polymorphism and proteinuria in childhood IgA nephropathy. Pediatr Nephrol 19: 144-147.
24. Schmidt S, Giessel R, Bergis KH, Strojek K, Grzeszczak W, et al. (1996) Angiotensinogen gene M235T polymorphism is not associated with diabetic nephropathy. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 11: 1755-1761.
25. Solini A, Giacchetti G, Sfriso A, Fioretto P, Sardu C, et al. (1999) Polymorphisms of angiotensin-converting enzyme and angiotensinogen genes in type 2 diabetic sibships in relation to albumin excretion rate. Am J Kidney Dis 34: 1002-1009.
26. Buraczynska M, Ksiazek P, Zaluska W, Spasiewicz D, Nowicka T, et al. (2002) Angiotensin II type 1 receptor gene polymorphism in end-stage renal disease. Nephron 92: 51-55.
27. Coll E, Campos B, Gonzalez-Nunez D, Botey A, Poch E (2003) Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency. J Nephrol 16: 357-364.
28. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, et al. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346.
29. Hunley TE, Julian BA, Phillips JA 3rd, Summar ML, Yoshida H, et al. (1996) Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 49: 571-577.
30. Amoroso A, Danek G, Vatta S, Crovella S, Berrino M, et al. (1998) Polymorphisms in angiotensin-converting enzyme gene and severity of renal disease in Henoch-Schoenlein patients. Italian Group of Renal Immunopathology. Nephrol Dial Transplant 13: 3184-3188.
31. van Dijk MA, Breuning MH, Peters DJ, Chang PC (2000) The ACE insertion/ deletion polymorphism has no influence on progression of renal function loss in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 15: 836-839.
32. Doria A (1998) Genetic markers of increased susceptibility to diabetic nephropathy. Horm Res 50 Suppl 1: 6-11.
33. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, et al. (1994) Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43: 384-388.
34. Schmidt S, Schone N, Ritz E (1995) Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. Kidney Int 47: 1176-1181.
35. Parving HH, Tarnow L, Rossing P (1996) Genetics of diabetic nephropathy. J Am Soc Nephrol 7: 2509-2517.
36. Epstein M (2001) Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 37: 677-688.
37. Ribstein J, Du Cailar G, Fesler P, Mimran A (2005) Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 16: 1320-1325.
38. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, et al. (1998) Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 32: 198-204.
39. Casiglia E, Tikhonoff V, Mazza A, Rynkiewicz A, Limon J, et al. (2005) C-344T polymorphism of the aldosterone synthase gene and blood pressure in the elderly: a population-based study. J Hypertens 23: 1991-1996.
40. Tsujita Y, Iwai N, Katsuya T, Higaki J, Ogihara T, et al. (2001) Lack of association between genetic polymorphism of CYP11B2 and hypertension in Japanese: the Suita Study. Hypertens Res 24: 105-109.
41. Tsukada K, Ishimitsu T, Teranishi M, Saitoh M, Yoshii M, et al. (2002) Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. J Hum Hypertens 16: 789-793.
42. Fisher ND, Hurwitz S, Jeunemaitre X, Hopkins PN, Hollenberg NK, et al. (2002) Familial aggregation of low-renin hypertension. Hypertension 39: 914-918.
43. Nicod J, Frey BM, Frey FJ, Ferrari P (2002) Role of the alpha-adducin genotype on renal disease progression. Kidney Int 61: 1270-1275.
44. Beeks E, van der Klauw MM, Kroon AA, Spiering W, Fuss-Lejeune MJ, et al. (2004) Alpha-adducin Gly460Trp polymorphism and renal hemodynamics in essential hypertension. Hypertension 44: 419-423.
45. Bianchi G, Manunta P (2004) Adducin, renal intermediate phenotypes, and hypertension. Hypertension 44: 394-395.
46. Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, et al. (1998) Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 31: 666-673.
47. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ (2004) Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 164: 1519-1524.
48. Hankinson SE, London SJ, Chute CG, Barbieri RL, Jones L, et al. (1989) Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem 35: 2313-2316.
49. (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266.
50. Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D, Curhan GC (2003) The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med 138: 460-467.
51. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G (2003) Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138: 98-104.
52. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, et al. (1996) Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2: 405-411.
53. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin MC, et al. (1996) Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens 14: 199-207.